Balancing Acts: An Analysis of Food and Drug Administration Letters about Direct-to-Consumer Advertising Violations

Abstract

Traditionally, physicians have considered themselves the gatekeepers to health care and have desired (and received) tight control over information conveyed to patients. Approval by the Food and Drug Administration (FDA) of direct-to-consumer (DTC) advertising changes this dynamic. The FDA is charged with promoting public health by reviewing clinical research and by taking timely, appropriate action on the marketing of regulated products. In addition, the FDA must ensure that human drugs are safe and effective. To accomplish this, the FDA must balance drug marketers’ desires to provide persuasive advertising messages with the concerns of several other groups about the effects of DTC messages on both the cost of medical care and the quality of patient interaction. The FDA must also balance these concerns with First Amendment protection of commercial speech. This study investigates the FDA's perceptions of the problems with DTC advertising. To accomplish this, the author examines FDA letters to pharmaceutical manufacturers about concerns about advertising messages that do not meet the guidelines established by the FDA. The author also provides suggestions about where the FDA should put its resources to best address these concerns: enhanced guidelines, consumer involvement, and intra-agency cooperation.

Get full access to this article

View all access options for this article.

References

Advertising Age (1998), “FDA Warned,” 69(32), 10.

Aiken

Kathryn J.

(2000), “Direct-to-Consumer Advertising of Prescription Drugs: Current Issues,” paper presented at the Advertising Club of New York, New York (October 8).

Baylor-Henry

Minnie V.

, and Rose

Janet L.

(2003), “Communicating with FDA's Advertising Groups,” in How to Work with the FDA, 2d ed., Wayne

L. Pines

, ed. Hagerstown, MD: Food and Drug Law Institute, 35–50.

Belkin

Lisa

(2001), “Primetime Pushers,” Mother Jones, 18(March-April), 31–37.

Bunis

Dena

(2000), “Direct to You,” (accessed April 4, 2003), [available at http://www.salon.com/health/feature/2000/02/23/drug_ads].

Calfee

John

(1997), Fear of Persuasion: A New Perspective on Advertising and Regulation. London: Agora.

Calfee

John

(2002), “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs,” Journal of Public Policy & Marketing, 21(Fall), 174–92.

Charatan

Fred

(2000), “US Prescription Drug Sales Boosted by Advertising,” BMJ: British Medical Journal, 321(7264), 783.

DTC Perspectives (2002), “Interview with Dr. Nancy M. Ostrove,” (accessed April 17, 2002), [available at http://www.DTCperspectives.com].

10.

Elliott

Victoria Stagg

(2003), “FDA Chief Pledges Changes to Direct-to-Consumer Advertising Guidelines,” (accessed May 14, 2003), [available at http://www.ama-assn.org/sci-pubs/amnews/pick_03/hlsd0428.htm].

11.

FDA (1995), Direct-to-Consumer Promotion. Silver Springs, MD: FDA.

12.

FDA (1997a), “Letter to Schering,” (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/mar97/claritins.pdf].

13.

FDA (1997b), “Letter to Searle,” (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/nov97/n20552_coverahs.pdf].

14.

FDA (1998a), “Letter to Pharmacia,” (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/mar98/6421.pdf].

15.

FDA (1998b), “Letter to Novartis,” (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/jan99/lescol.pdf].

16.

FDA (2001a), “Letter to Astra,” (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/2001/10205.pdf].

17.

FDA (2001b), “Letter to Glaxo,” (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/2001/dd10171.pdf].

18.

FDA (2003a), “FDA's Mission,” (accessed May 15, 2003), [available at http://www.FDA.gov/opacom/morechoices/mission.html].

19.

FDA (2003b), “Global Summit 2003,” (accessed May 15, 2003), [available at http://www.FDA.gov/cder/ddmac/globalsummit2003.index.htm].

20.

FTC (2003), “Information for Business,” (accessed May 20, 2003), [available at http://www.ftc.gov/bcp/conline/pubs/buspubs/ad-faqs.htm].

21.

Goetzl

David

, Klaassen

Abbey

, Teinowitz

Ira

, and Sanders

Lisa

(2001), “Dose of Reality,” Advertising Age, 72(30), 1–2.

22.

Hall

(2001), “Claritin and Schering-Plough: Prescription for Profit,” The New York Times, (accessed), [available at http://www.nytimes.com/2001/03/11/magazine/11CLARITIM.html].

23.

Henney

Jane E.

(2000), “Challenges in Regulating Direct-to-Consumer Advertising,” msJAMA, 284(6), 2242.

24.

McClellan

Mark

(2003), “Speech before FDLI,” (accessed May 15, 2003), [available at http://www.FDA.gov/oc/speeches/2003/fdli0401.html].

25.

McInturff

Bill

(2001), “While Critics May Fret, Public Likes DTC Ads,” Advertising Age, 72(March 26), 24.

26.

National Institute for Healthcare Management Foundation (2001), Prescription Drugs and Mass Media Advertising. Washington, DC: National Institute for Healthcare Management Foundation.

27.

Nayyar

Seema

(1992), “Green Light for Drug Ads,” Adweek, 29(24), 9.

28.

Nordenberg

Tamar

(1998), “Direct to You: TV Drug Ads That Make Sense,” (accessed February 20, 2003), [available at http://www.FDA.gov/FDAc/features/1998/198_ads.html].

29.

Perrault

William D.

Jr. , and Leigh

Lawrence E.

(1989), “Reliability of Nominal Data Based on Qualitative Judgments,” Journal of Marketing Research, 26(May), 135–48.

30.

Peterson

Melody

(2002), “TV Ads Spur a Rise in Prescription Drug Sales,” The New York Times, (March 8), B4.

31.

Pharmaceutical Research and Manufacturers of America (2000), “Backgrounder and Facts: Direct to Consumer Advertising,” (accessed February 11, 2002), [available at http://www.phrma.org/publications/backgrounders/other/DTC.phtml].

32.

Roth

Martin S.

(1996), “Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications,” Journal of Public Policy & Marketing, 15(Spring), 63–75.

33.

Schommer

John

, Doucette

William

, and Mehta

Bella

(1998), “Rote Learning After Exposure to a Direct-to-Consumer Television Advertisement for a Prescription Drug,” Clinical Therapeutics, 20(3), 617–31.

34.

Shaw

Michael

(2001), “The DTC Dilemma,” Pharmaceutical Executive, (accessed February 20, 2003), [available at http://www.HealthcareMedia.com].

35.

Sibley

Charlotte E.

(2000), “DTC Advertising Studies,” research report, Coalition for Healthcare Communication, (April 10).

36.

Tanouye

Elyse

(2000), “US Develops Expensive Habit with Drug Sector Growth Spurt,” The Wall Street Journal Interactive Edition, (January 19), [available at http://www.msnbc.com/news/215163.asp].

37.

U.S. GAO (2002), FDA Oversight of Direct-to-Consumer Advertising Has Limitations. Washington, DC: U.S. GAO.

38.

Woods

Bob

(2001), “Additional Side Effects,” (accessed April 10, 2003), [available at http://www.promomagazine.com/ar/marketing_additional_side_effects/].